The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Reassessing free light chain criteria used in the diagnosis of MM
In this study, Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights a study which investigated the free light chain criteria used in the 2014 IMWG diagnostic criteria, and implications of this study in the future treatment of multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research Funding: GSK, Amgen, Daiichi Sankyo, Cosette
Advisory board: BMS
Consultancy: Curio Science LLC, Intellisphere LLC
Membership on an entity’s Board of Directors or advisory committees: GSK
